Publicaciones GEIS

• Comunicaciones a Congresos Internacionales
• Publicaciones Internacionales
• Capítulos en libros - Monografías

Comunicaciones a Congresos Internacionales

1. López-Pousa A. First-line high dose ifosfamide in patients with advanced soft-tissue sarcoma. A phase II study of the spanish group for research on sarcomas. 21 St  ESMO Congress.Vienna, Noviembre 1996.
   
   
2. Buesa JM, López-Pousa A, Antón A, Martín J, García del Muro X, Bellmunt J,  Poveda A, Escudero P. Phase II trial of first–line high-dose Ifosfamide in advanced soft tissue sarcoma (STS) patients. Poster. 33nd ASCO. Denver, Mayo 1997.  Proc Am Soc Clin Oncol 1997;16:498a.
   
   
3. López-Pousa A, Montalar J, Buesa JM, Maurel J, Martín J, Cassinello J, Sevilla I, de las Peñas R, Cruz J, Balañá C, García del Muro X, Poveda A. High-Dose Ifosfamide and Doxorubicin in advanced previously untreated soft tissue sarcoma patients. a phase II study of the Spanish Group for Research in Sarcomas (GEIS). 4th CTOS Annual Scientific Meeting. Vancouver, November 1998.
   
   
4. López-Pousa A, Montalar J, Buesa JM, Maurel J, Martín J, Cassinello J;  Sevilla I; de las Peñas R, Cruz J, Balañá C. First-line doxorubicin and high-dose ifosfamide (DHI) in advanced soft tissue sarcoma (STS) patients. A phase II study of the Spanish Group for Research on Sarcomas. Abstract 564. 23rd ESMO Congress. Atenas, Noviembre 1998.
   
   
5. López-Pousa A, Buesa JM, Montalar J, Martín J, Maurel J, García del Muro X, de las Peñas R, Cruz J, Cassinello J, Sevilla I, Balañá C, Casado A, Bover I, Paredes A, Carles J, Poveda A. Phase II trial of Doxorubicin and High-dose Ifosfamide in advanced previously  untreated soft tissue sarcoma patients. a study of the Spanish Group for Research in Sarcomas (GEIS). Poster Discussion. 36th ASCO. Atlanta, mayo 1999. Proc Am Soc Clin Oncol  1999;18:544a.
   
   
6. Poveda A, López-Pousa A, Martín J, Buesa JM, Balañá C, Menéndez D. Liposomal Doxorubicin (Caelyx) in advanced soft tissue sarcoma patients. A phase II study of  the Spanish Group for Research in Sarcomas (GEIS). Comunicación. 36th ASCO. Atlanta, mayo 1999. Proc Am Soc Clin Oncol  1999;18:553a.
   
   
7. Buesa JM, Teijido PG, Galbe M, López-Pous A, García del Muro X, Martín J, Antón A, Montalar J, de las Peñas R, Cruz J, Escudero P, Fra J, Menéndez D, Poveda A. Nephrotoxicity of continuous infusion ifosfamide. A study of the Spanish Group for research on Sarcomas (GEIS). Reunión de la C.T.O.S., Washington, Octubre 1999
   
   
8. Buesa JM, Teijido PG, Galbe M, López-Pousa A, García del Muro X; Martín J,  Antón A, Montalar J, de las Peñas R, Cruz J, Escudero P, Fra J, Menéndez D, Poveda A. Nephrotoxicity of continuous infusion ifosfamide. A study of the Spanish Group for Research on Sarcomas (GEIS)”. Abstract 0037. 5th CTOS congress. Arlington, Octubre 1999.
   
   
9. López-Pousa A, Buesa JM, Montalar J, Martín J, Maurel J, García del Muro X, de las Peñas R, Cruz J, Cassinello J, Sevilla I, Balañá C, Casado A. First-line Doxorubicin and scalated High-dose Ifosfamide in advanced soft tissue sarcoma patients a phase II study of the Spanish Group for Research in Sarcomas (GEIS). Comunicación-Poster- Sesion. 36th ASCO New Orleans, Louisiana, mayo 2000.
   
   
10. López-Pousa A, Buesa JM, García del Muro X, Manuel J, Balañá C, Casado A, Bellmunt J, Poveda A, Martín J, Martínez-Trufero J, de las Peñas R, Bover I. Sequential High-dose Doxorubicin and High-dose Ifosfamide in advanced previously untreated soft tissue sarcomas of the adult. A multicenter phase II  study of the Spanish Group for Reseach in Sarcomas (GEIS). Poster – Discussion. 37th  ASCO Annual Meeting. San Francisco,  mayo 2001. Proc Am Soc Clin Oncol  2001;20:353a
    
    
11. García del Muro X, López-Pousa A, Buesa JM, Martín J, Bover I, Escudero P, Casado A, Martínez-Trufero J, Maurel J. Temozolomide as a  6-week continuous oral schedule in advanced soft tissue sarcomas: a phase II study of the Spanish Group for Reseach in Sarcomas (GEIS). Poster – Discussion. 37th  ASCO Annual Meeting. San Francisco,  mayo 2001. Proc Am Soc Clin Oncol  2001;20:354a.
    
    
12. López-Pousa A, Buesa JM, García del Muro X, et al. Sequential high-dose doxorubicin (Dx) and High dose Ifosfamide (IF) in advanced previosly untreated soft tissue sarcoma of the adult (STS). A multicenter phase II study of the Spanish Group for Research on Sarcomas (GEIS). Proc Am Soc Clin Oncol  2001;20:353.
    
    
13. García del Muro X, López-Pousa A, Buesa JM, Martín J, Poveda A, Bover I, Escudero P, Martínez-Trufero J, Casado A. Temozolomide as a 6 week continuous oral schedule in advanced soft tissue sarcomas: A phase II study of the Spanish Group for Research on Sarcomas (GEIS). Proc. Am Soc Clin Oncol 2001; 20: 1412.
    
    
14. García del Muro X, López-Pousa A, Buesa JM, Martín J, Poveda A, Bover I, Escudero P, Martínez-Trufero J, Casado A. Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcoma: A phase II trial of the Spanish Group for Research on Sarcomas (GEIS). 2001 CTOS Annual Meeting Posters— Medical Oncology.
    
    
15. Maurel J, Buesa JM, López-Pousa A, García del Muro X, Martínez-Trufero J, de las Peñas R, Escudero P, Piera JM, Martín J, Casado A, Sevilla I, Balañá C, Bover I,  Montalar J, Poveda A, Cassinello J, Cruz J, Carles J, Camps C, Bellmunt J. High-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma patients. An analysis of prognostic factors: A study of the Spanish Group for Research on Sarcomas (GEIS). Proc Am Soc Clin Oncol 2002;21(407ª):a-1627.
    
    
16. Buesa JM, Teijido PG, Fra J, et al. Treatment of ifosfamide (IFOS) encephalopathy with intravenous thiamine. Poster Discussion. Proc Am Soc Clin Oncol 2002;21:409,a.
    
    
17. Martín J, López-Pousa A, Bover I, Sevilla I, Cruz J, Buesa JM, Escudero P, Blanco R, Poveda A, Casado A, García del Muro X, Maurel J, Piera JM, Maestu I, Casado S, Carles J, González de Sande LM, Montalar J, Martínez-Trufero J, de las Peñas R,  Rifa J. Malignant Gastointestinal stromal tumors and uterine sarcomas: differences in prognostic factors for survival. A clinical approach. Study of the Spanish Group for Research in sarcomas (GEIS). Poster Discussion. Proc Am Soc Clin Oncol 2002;21(411ª):a-1641.
    
    
18. López-Pousa A, Buesa JM, Martín J, Casado A, Balañá C, García del Muro X, Poveda A. Phase I/II trial of Doxorubicin and dose escalation prolonged infusion Gemcitabine as first line treatment in advanced soft tissue sarcomas. A study of the Spanish Group for Research in Sarcomas (GEIS). General Poster Session. Proc. Am Soc Clin Oncol 2003; 22(825):3317.
    
    
19. Buesa JM, Fra J, López-Pousa A, Losa R, Mareque B, Sierra M, Una E, Blay P. Phase I trial of Dacarbacine (DTIC) and prolonged infusion Gemcitabine in patients with soft Tissue  sarcoma. Poster Discussion. Proc Am Soc Clin Oncol vol 2003;22:3296.
    
    
20. Martín J, Poveda A, Llombart-Bosch A, Ramos R, García del Muro X, Martínez-Trufero J, de Juan A, Maurel J, Losa F, Buesa JM. Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of gastrointestinal stromal tumors (GIST). A GEIS study. General Poster Session. Proc Am Soc Clin Oncol 2004;22:9029.
    
    
21. López-Pousa A, Buesa JM, Casado A, García del  Muro X, Poveda A, Maurel J, Martín J, Balañá C, Martínez-Trufero J, Martín J, Poveda A, Llombart-Bosch A, Ramos R, García del Muro X, Martínez-Trufero J. Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Resarch in Sarcomas (GEIS). General Poster Session. Proc Am Soc Clin Oncol 2004;22:9033.
    
    
22. García del Muro X, Fra F, Martínez-Trufero J, Sevilla I, Escudero P, Cruz J, Martín J, Casado A, Arrazubi V, Buesa JM. Temozolomide in the treatment of gynecological leiomyosarcoma: A Spanish Group for Resarch in Sarcomas (GEIS) study. Poster Discussion. Proc Am Soc Clin Oncol 2005;22:9030.
    
    
23. García del Muro X, Poveda A, Buesa JM, Martínez-Trufero J, González de Sande LM, Calvo E, Escudero P, López-Pousa A, Fabregat X, Casado A Phase II Trial of Temozolomide as First-line Treatment for Patients with Advanced Gynecological Sarcoma: A Spanish Group for Research on Sarcomas (GEIS) and Spanish Ovarian Cancer Research Group (GEICO) Study. Poster Discussion. Proc Am Soc Clin Oncol 2006 juny Atlanta.
    

Publicaciones Internacionales

1. Buesa JM, Fra J, Antón A, López-Pousa A, Martín J, García del Muro X, Escudero P, Casado A, Poveda A. Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol. 1998 Jul;9(7):783-5. PMID: 9739447 [PubMed - indexed for MEDLINE]
   
   
2. Buesa JM, López-Pousa A, Martín J, Antón A, García del Muro X, Bellmunt J, Arranz F, Valenti V, Escudero P, Menéndez D, Casado A, Poveda A. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol. 1998 Aug;9(8):871-6. PMID: 9789610 [PubMed - indexed for MEDLINE]
   
   
3. Buesa JM, Teijido PG, Losa R, Fra J. Treatment of Ifosfamide Encephalopathy with Intravenous Thiamin. Clinical Cancer Resarch. 2003 Oct 9:4636-7.
   
   
4. Maurel J, Fra J, López-Pousa A, García del Muro X, Balañá C, Casado A, Martín J, Martínez-Trufero J, de las Peñas R, Buesa JM; Spanish Group for Research on Sarcomas (GEIS). Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer. 2004 Apr 1;100(7):1498-506. PMID: 15042685 [PubMed - indexed for MEDLINE]
   
   
5. Maurel J, Buesa JM, López-Pousa A, García del Muro X, Quintana MJ, Martín J, Casado A, Martínez-Trufero J, de las Peñas R, Balañá C. Salvage surgical resection after high-dose ifosfamide (hdif) based regimens in advanced soft tissue sarcoma (asts): a potential positive selection bias – a studi of Spanish group for research on sarcomas (GEIS). J Surg Oncol. 2004 Oct 1;88(1):44-9. PMID: 15384088 [PubMed - indexed for MEDLINE]
   
   
6. Buesa JM, Losa R, Fernández A, Sierra M, Esteban E, Díaz A, López-Pousa A, Fra J. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer. 2004 Nov 15;101(10):2261-9. PMID: 15484216 [PubMed - indexed for MEDLINE]
   
   
7. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD. Consensus meeting for the management of gastroinstestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005 Apr;16(4):566-78. PMID: 15781488 [PubMed – indexed for MELINE]
   
   
8. García del Muro X, López-Pousa A, Martín J, Buesa JM, Martínez-Trufero J, Casado A, Poveda A, Cruz J, Bover I, Maurel J. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. Cancer. 2005 Aug 30;104(8):1706-12. PMID: 16134177 [PubMed - as supplied by publisher]
   
   
9. Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, García del Muro X, Maurel J, Calabuig S, Gutierrez A, González de Sande JL, Martínez-Trufero J, de Juan A, Laínez N, Losa F, Alija V, Escudero P, Casado A, García P, Blanco R, Buesa JM. Deletions Afecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS).J Clin Oncol. 2005 Sep 1;23(25):6190-8. PMID: 16135486 [PubMed - in process]
   
   
10. López-Pousa A, Martín J, Montalar J, de las Peñas, R, García del Muro X, Cruz J, Maurel J, Escudero P, Casado A, Buesa JM, Martínez-Trufero J, Bover I, Sevilla I, Balañá C, Paredes A, Carles J, Vicent J, Cassinello J. Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma. Volume 2006; Article ID 26986, Pages 1-8.
    
    
11. Poveda A, López-Pousa A, Martín J, García del MuroX, Bernabé R, Casado A, Balañá C, Sanmartín O, Menéndez MD, Escudero P, Cruz J, Belyakova E, Menéndez D, Buesa JM. Phase II clinical trial with pegylated liposomal doxorubicin (Caelyx®) / Doxil®) and quality of life evaluation (EORTC QLQC30) in adult patients with advanced soft tissue sarcomas. A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma volumen 9 (2005): 127-132.
    
    
12. Losa R, Fra J, López-Pousa A, Sierra M, Goitia A, Uña E, Nadal R, García del Muro X, Gión M, Maurel J, Escudero P, Esteban E, Buesa JM. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.  Cancer Chemother Pharmacol. DOI 10.1007/s00280-006-0263-0 May 2006.
    
    
13. López-Pousa A, Losa R, Martín J, Maurel J, Fra J, Sierra M, Casado A, García del Muro X, Poveda A, Balaña C, Martínez-Trufero J, Esteban E, Buesa JM. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. British Journal of Cancer (2006), 1 –6.
    
    
    
14. López-Pousa A, Martín J, Montalar J, de las Peñas, R, García del Muro X, Cruz J, Maurel J, Escudero P, Casado A, Buesa JM, Martínez-Trufero J, Bover I, Sevilla I, Balañá C, Paredes A, Carles J, Vicent J, Cassinello J. Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma. Volume 2006; Article ID 26986, Pages 1-8.
    
    
15. Losa R, Fra J, López-Pousa A, Sierra M, Goitia A, Uña E, Nadal R, García del Muro X, Gión M, Maurel J, Escudero P, Esteban E, Buesa JM.- Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer Chemother Pharmacol. 2007 Feb;59(2):251-9.
    
    
16. Guías de la práctica Clínica en GIST Clinical & Translational Oncology”, vol. 7, Ext. 2, 2005, / Cirugía Española, vol. 84, Ext. 1 / Clinical & Translational Oncology 2008-1.
    
    
17. Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas. Journal of Clinical Oncology. Marzo 2009.
    
    
18. J Martin; A Gutierrez; J Garcia del Muro; J Maurel; JL González de Sande; J Martinez; A de Juan; N Lainez , F Losa and A Poveda.Time Dependence of Critical Deletions as Prognostic Factor for Relapse Free Survival (RFS) in localised GIST. A Spanish Group for Sarcoma Research (GEIS) Study.

Capítulos en libros - Monografías

1. Poveda A, Querejeta A, Buesa JM. Capítulo 14.1: Sarcomas en partes blandas. EN: H Cortés-Funes, E Díaz-Rubio, J García-Conde, JR Germá Lluch, V Guillem Porta, JJ López López, JA Moreno Nogueira, G Pérez Manga. (eds.), Oncología Médica, Madrid, Nova Sidonia Oncología – Grupo Aula Medica, S.A. 1999: 1041-1060. ISBN Tomo 2: 84-7885-209-3.
   
   
2. López-Pousa A, Majó J, Martín J. Capítulo 14.2: Sarcomas óseos y neuroectodérmicos del adulto. EN: H Cortés-Funes, E Díaz-Rubio, J garcía-Conde, JR Germá Lluch, V Guillem Porta, JJ López López, JA Moreno Nogueira, G Pérez Manga. (eds.), Oncología Médica, Madrid, Nova Sidonia Oncología – Grupo Aula Medica, S.A. 1999: 1061-1093. ISBN Tomo 2: 84-7885-209-3.
   
   
3. Maurel J, López-Pousa A, Buesa JM, García del Muro X, Balañá C, Casado A, Martínez-Trufero J, de las Peñas R, Martín j, Bellmunt J. Sequential high-dose doxorubicin (DXR) and high-dose ifosfamide (IF) in advanced previously untreated soft tissue sarcomas of the adult (STS). A multicenter phase II study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma 5 (Suppl 1): S32, 2001. Resumen.
   
   
4. García del Muro X, López-Pousa A, Buesa JM, Martín J, Poveda A, Bover I, Escudero P, Casado A, Martínez-Trufero J, Casado A. Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcomas (STS): A phase II trial of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma 5 (Suppl 1): S33, 2001. Resumen.
   
   
5. Martín J, Balañá C, López-Pousa A (Director científico). Nuevas Fronteras en Sarcomas, Incidencia, patología y Consejo Genético en Sarcomas.  1, 2004.
   
   
6. Buesa JM, Azaro A, Blay P, López-Pousa A (Director científico). Nuevas Fronteras en Sarcomas, Factores Clínico-Biológicos y Pronóstico de los Sarcomas de Partes Blandas en el Adulto.  2, 2004.
   
   
7. Gallego R, Vázquez S, García del Muro X, Maurel J, López-Pousa A (Director científico).  Nuevas Fronteras en Sarcomas, Nuevos Fármacos en el Tratamiento de los Sarcomas. 3, 2004.
   
   
8. López-Pousa A. Capítulo 16: Sarcomas óseos, de partes blandas y del estroma gastrointestina. EN: Guía práctica de Tumores Sólidos – Esquemas de diagnóstico y tratamientos en neoplasias sólidas, Albert Abad, Pere Gascón, Eduardo Díaz-Rubio, 1ª Edición, Team Project 2004:196-224.
   
   
9. de Álava E, López-Pousa A (Director científico). Nuevas Fronteras en Sarcomas, Patología Molecular en el Diagnóstico y Tratamiento de los Sarcomas de Hueso y Tejidos Blandos. 4, 2005.
   
   
10. Poveda A, Safont MJ, Gallego O, López-Pousa A (Director científico). Nuevas Fronteras en Sarcomas, Tratamiento Adyuvante de los Sarcomas de Partes Blandas. 5, 2005.
    
    
11. Poveda A, Maurel J, Martín J, Artigas V, Casado A, Cervra J, López-Pousa A, Ortega F, Ortega L, Ramos R, Ginés A, Safont MJ, Buesa JM. Guía de práctica clínica en los tumores estromales gastrointestinales. Grupo Español de Investigación en Sarcomas (GEIS). Clinical & Tralational Oncology, Volumen 7, Extraordinario 2, 2005. ISSN: 1699-048X.
    
    
12. Poveda A, Maurel J, Martín J, Artigas V, Casado A, Cervra J, López-Pousa A, Ortega F, Ortega L, Ramos R, Ginés A, Safont MJ, Buesa JM. Guía de práctica clínica en los tumores estromales gastrointestinales. Grupo Español de Investigación en Sarcomas (GEIS). Cirugía Española, Volumen 78, Extraordinario 2, Octubre 2005. ISSN: 0009-739X.
    
    
13. Casado A, López-Pousa A (Director científico). Nuevas Fronteras en Sarcomas, Tumores del Estroma Gastrointestinal (GIST). 6, 2005.